Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budigalimab Monotherapy and Combinations in Advanced Solid Tumors
NCT03000257Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2016
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 1, open-label trial of budigalimab in solid tumor (advanced stage), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and 1 more (3 arms), sponsored by AbbVie Inc. Primary endpoints: Recommended Phase 2 Dose up to 6 months, Maximum Tolerated Dose up to 6 months and 5 more. Started Dec 2016; status: completed.
02
Drugs
budigalimab
03
Conditions
solid tumor (advanced stage)small cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03000257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03000257.